or Try an Advanced Search...

    Alnylam Pharmaceuticals Stocks List

    Symbol Grade Name % Change
    RGLS B Regulus Therapeutics Inc. 1.35
    PRQR D ProQR Therapeutics B.V. -2.74
    ALNY F Alnylam Pharmaceuticals, Inc. -0.32
    VIR F Vir Biotechnology, Inc. -5.22
    View As Page of Charts
    Related Industries: Biotechnology
    Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm

    Related ETFs - A few ETFs which own one or more of the above listed Alnylam Pharmaceuticals stocks.

    Symbol Grade Name Weight
    GERM F ETFMG Treatments Testing and Advancements ETF 9.33
    GNOM F Global X Genomics & Biotechnology ETF 4.77
    BTEC D Principal Healthcare Innovators Index ETF 3.51
    FBT D First Trust Amex Biotech Index Fund 2.66
    IBBQ C Invesco Nasdaq Biotechnology ETF 2.19
    View all Alnylam Pharmaceuticals ETFs...
    Compare ETFs
    Compare BTEC to FBT Compare FBT to IBBQ Compare GERM to GNOM

        Alnylam Pharmaceuticals Stocks Recent News

        Date Stock Title
        Apr 24 VIR What Makes Vir Biotechnology (VIR) a New Buy Stock
        Apr 23 PRQR ProQR Nominates Martin Maier, PhD to Board and Announces Annual Meeting of Shareholders to be Held May 22, 2024
        Apr 22 PRQR ProQR Highlights Upcoming Presentations on Axiomer™ RNA Editing at ASGCT 27th Annual Meeting
        Apr 19 ALNY How Is The Market Feeling About Alnylam Pharmaceuticals?
        Apr 19 PRQR ProQR Achieves Successful Defense of New Challenge to its Axiomer™ IP Portfolio
        Related Industries: Biotechnology
        Related Stock Lists: Biopharmaceutical Biotechnology Oligonucleotide Regulus Therapeutics Therapeutic Gene Modulation Acute Intermittent Porphyria Alpha 1 Antitrypsin Deficiency Amyloid Amyloidosis Antitrypsin Deficiency Atherosclerosis Beta Thalassemia Blastoma Carcinoma Cholesterol Clinical Development Coronavirus Cystic Fibrosis Deficiency Dimm
        Alnylam Pharmaceuticals

        Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

        More about Alnylam Pharmaceuticals
        Browse All Tags